Yttrium is a metal of the rare earth group of elements. A radioactive form of yttrium may be attached to a monoclonal antibody or other molecule that can locate and bind to cancer cells and be used to diagnose or treat some types of cancer.
Many types of cancer could be more easily treated if they were detected at an earlier stage. MIT researchers have now developed an imaging system, named "DOLPHIN," which could enable them to find tiny tumors, as small as a couple of hundred cells, deep within the body.
Targeted tumor radiation provides a feasible treatment option for children with difficult-to-treat liver cancer, according to a new study published today in the journal Pediatric Blood and Cancer.
Emerging cancer nanotechnology enables target-delivery of substantial payloads of drugs to cancer sites with concomitant reduction of side-effects due to the lesser accumulation in the critical organs.
A new nuclear medicine imaging method could help diagnose widespread tumors, such as breast, colon, pancreas, lung and head and neck cancer better than current methods, with less inconvenience to patients and with equal or improved accuracy.
The final results of the palliative cohort of the SORAMIC study in patients with unresectable, locally advanced primary liver cancer have confirmed no clinical advantage to adding selective internal radiation therapy to standard sorafenib treatment compared with using sorafenib alone.
Patients with advanced or inoperable Hepatocellular Carcinoma (HCC) who usually received one or two treatments with liver-directed SIR-Spheres Y-90 resin microspheres in the 459-patient French SARAH study had similar survival compared to patients who received standard twice-daily systemic treatment with sorafenib, but with less than half the number and significantly fewer severe treatment-related adverse effects and significantly better Quality of Life, according to data presented here at The International Liver Congress™ 2017.
Aggressive neuroendocrine cancer is something of a dark horse--a rare, elusive and persevering force linked to discouraging long-term survival rates.
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that ZEVALIN is now available at hospitals in Hong Kong to patients with indicated non-Hodgkin's lymphoma (NHL), including at Hong Kong Sanatorium & Hospital.
A new treatment for liver cancer developed by the University Medical Center (UMC) Utrecht has received the European CE mark for quality and safety.
SARAH, a large French study of patients with advanced, inoperable primary liver cancer (hepatocellular carcinoma, or HCC) has completed patient enrolment, exceeding its 400-patient target, according to its principal investigator, Professor Valérie Vilgrain MD, PhD, Department of Radiology, Beaujon Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) and Université Paris Diderot, Sorbonne Paris Cité, France.
Using two biocompatible parts, University at Buffalo researchers and their colleagues have designed a nanoparticle that can be detected by six medical imaging techniques.
Scientists at the U.S. Naval Research Laboratory Materials Science and Technology Division have developed a novel one-step process using, for the first time in these types of syntheses, potassium superoxide (KO2) to rapidly form oxide nanoparticles from simple salt solutions in water.
Eckert & Ziegler Radiopharma GmbH has received a recommendation from the European Medicines Agency for approval of its pharmaceutical 68Ge/68Ga generators.
Research conducted by Lindsay R. Sklar, M.D., Christopher T. Burnett, M.D., F.A.A.D., Jill S. Waibel, M.D., F.A.A.D., Ronald L. Moy, M.D., F.A.A.D., and David M. Ozog, M.D., F.A.A.D., was selected as Editor’s Choice for the April 2014 issue of Lasers in Surgery and Medicine.
Advanced Medical Isotope Corporation ("AMIC"), a company engaged in the development, production and distribution of medical isotopes focused on yttrium-90 brachytherapy devices, today announced that it has received a response from the FDA to its pre-market notification to the FDA pursuant to Section 510(k) of the U.S. Food, Drug and Cosmetic Act for its Yttrium-90 (Y-90) RadioGel(tm) patented brachytherapy cancer product.
Researchers at the Virginia Tech Carilion Research Institute have reported the first experimental evidence that supports the theory that a soccer ball-shaped nanoparticle commonly called a buckyball is the result of a breakdown of larger structures rather than being built atom-by-atom from the ground up.
Spectrum Pharmaceuticals, Inc., a biotechnology company with fully-integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that, through a wholly-owned subsidiary, the company entered into an agreement to acquire Talon Therapeutics, Inc., a biopharmaceutical company based in South San Francisco, California, and expects to complete the acquisition within one day.
Peptide-receptor radionuclide therapy has been a subject of growing research on neuroendocrine tumors, which take up residence in a variety of organs replete with nerve cells that respond to hormone signaling.
Researchers at Aldrich Materials Science, a strategic technology initiative of Sigma-Aldrich Corporation have discovered an innovative way to design an important class of three-dimensional (3D) hybrid structures, Metal Organic Frameworks (MOFs), under completely liquid-free conditions.
Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology and hematology, today announced new clinical data presented in an oral presentation for ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use at the 17th Congress of the European Hematology Association (EHA).